Medicare AdvantagePrior AuthHigh impact
Non-preferred adalimumab products (Revised)
Humana·Rheumatology, Gastroenterology, Dermatology +2 more·Medicare Advantage
We identified it
Jul 2, 2026
Summary
Humana has revised its prior authorization policy for non-preferred adalimumab products on Medicare Advantage plans. This is a 1-day-old policy update that requires billing teams to verify authorization status before claims submission for non-preferred adalimumab formulations. The specific clinical criteria and preferred product alternatives are not detailed in the summary-only source provided.
Action Required
IMMEDIATE (Within 1 business day): Billing team must access the complete policy at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a56a5f2 to obtain specific prior authorization requirements for non-preferred adalimumab HCPCS codes. Update billing software to flag all claims containing non-preferred adalimumab products (J7291-J7298 family) for prior authorization verification BEFORE submission to Humana Medicare Advantage plans. Notify rheumatology, gastroenterology, and dermatology providers of the updated authorization process. Implement workflow to verify prior auth status in the Humana Mentor portal. Claims submitted without required prior authorization for non-preferred adalimumab products will be denied, resulting in billing delays and patient account issues. Do not process claims until complete policy details are reviewed and system rules are configured.